Antidepressants and suicide
Executive Summary
FDA's analysis of independently reviewed pediatric suicidality data for antidepressants will be discussed Sept. 13-14 during a joint meeting of the Psychopharmacologic Drugs Advisory Committee and the newly formed Pediatric Advisory Committee. The meeting is a follow-up to a Feb. 2 meeting where advisory committee members expressed concern about the high degree of variability and lack of categorization of suicide-related events (1"The Pink Sheet" Feb. 9, 2004, p. 35). FDA's handling of the pediatric data has sparked Congressional inquiries. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8 a.m. [To 2watch a webcast or order video/DVDs of this meeting, go to FDAAdvisoryCommittee.com.]...
You may also be interested in...
Antidepressant Warnings On Pediatric Suicide Need Immediate Strengthening
Strengthened warnings about the risk of suicide ideation and attempts among children taking antidepressant medications should be communicated to physicians and consumers as soon as possible, a joint FDA advisory committee told the agency Feb. 2
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.